Are amphiphysin antibodies a paraneoplastic neurologic marker?

Amphiphysin-IgG is a high-risk onconeural antibody and an important clue to paraneoplastic neurologic disease, but its interpretation must combine the neurologic syndrome, assay validity, and independent cancer assessment.

Clinical and tumor associations

• Amphiphysin antibodies are established markers in paraneoplastic neurologic syndromes, particularly stiff-person syndrome, encephalomyelitis, and sensory neuronopathy. They are classified in 2021 PNS-Care criteria as high-risk cancer-associated antibodies (>70% cancer association).
• Breast cancer and small-cell lung cancer (SCLC) are the principal associated malignancies. In a Mayo Clinic series of 20 antibody-positive patients with malignancy, 12 (63%) had breast cancer and 4 (22%) had SCLC; a published-case review found breast cancer in 20/47 and SCLC in 13/47 cases.
• Prostate cancer is not a typical association. A reported metastatic prostate adenocarcinoma case with stiff-person syndrome and high-titer CSF amphiphysin antibodies shows that the pairing can occur, but does not establish a predictable frequency or causal attribution in an individual patient. Ovarian cancer is also a less-common reported association.

Mechanistic and testing context

• Amphiphysin is an intracellular neuronal antigen. The syndrome is thought to arise primarily from a tumor-triggered, cytotoxic T-cell response, with the antibody serving mainly as a biomarker rather than proven direct mediator of neuronal injury.
• Positivity alone does not demonstrate active cancer or establish a paraneoplastic syndrome. Low-titer or serum-only commercial line-blot results, especially with an atypical phenotype, can be clinically irrelevant and should be confirmed by independent testing, ideally including tissue-based methods and antigen-specific assays; paired serum/CSF testing may help resolve discordance.

Clinical implications

• A confirmed result with a compatible phenotype warrants directed screening for breast cancer and SCLC, while not assuming that known or suspected prostate cancer explains the antibody.

Bottom line

• Amphiphysin antibodies strongly raise concern for an underlying malignancy-associated neurologic syndrome, especially breast cancer or SCLC, but require confirmation and systematic tumor evaluation; they are not proof of currently active malignancy.